Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases.

Biotechnology

Oncimmune

Ron is a qualified lawyer with over 18 years of experience in advising international companies, including those in the bio-technology and healthcare sector. Ron began his career in the corporate team of Allen & Overy, in its London, Hong Kong and Bangkok offices, before moving to Baker & McKenzie, the international law firm. Ron has also held senior in-house positions, including in Barclays Bank and Genus Plc, where he was interim General Counsel over a 12 month period.

Most recently Ron was Senior Counsel at Smith & Nephew plc, the London-listed global medical devices company, where he led the legal team supporting the European commercial operations. Ron was a member of Smith & Nephew’s UK management team and took part in its European leadership team.

Ron has extensive international experience, having spent several years working in Asia and regularly advising on international transactions.

Ron graduated from the University of Birmingham with an LLB in Law & Business Studies. He is admitted to practice law in England and Wales.

Ron Kirschner

Professor Winqvist is a Professor of Cellular Immunotherapy at the Karolinska Institute and Senior Consultant in Clinical Immunology at the Karolinska University Hospital. Professor Winqvist received his medical qualification in 1991 at the University of Uppsala. He then went on to achieve a PhD, focusing on experimental medicine and autoantigens in Addison’s disease. He held a post-doctoral position at the Scripps Research Institute in California for three years and was Chairman of the Swedish Clinical Immunology Society until 2017.

Ola S Winqvist

Dr. Roope is a General Practitioner and UK Clinical Lead for Cancer at the Royal College of General Practitioners. He is a Senior Clinical Advisor (Prevention and Early Diagnosis)​ at Cancer Research UK, and a member of the National Cancer Advisory Group. Dr. Roope trained at Cambridge University and the University of London graduating in 1987 with a Bachelor of Medicine and Surgery degree. In 2015, he was elected to Fellowship of the RCGP for contributions to Cancer Management.

Richard M. Roope

Dr. Pashayan is a Clinical Reader in Applied Health Research at University College London, a qualified GP and Honorary Consultant in Public Health at University College London Hospitals, as well as a member of the Breast Cancer Now Scientific Advisory Board. She received a MSc in Epidemiology from London School of Hygiene and Tropical Medicine and MSt in Public Health and PhD from the University of Cambridge before commencing a research career at the University of Cambridge, focusing on early detection, particularly in risk-stratified screening of cancer.

Nora Pashayan

Dr. Mallick is an Associate Professor at Stanford University. Originally trained as an engineer and biochemist, his research spans computational and experimental systems biology, cancer biology and nanotechnology. Dr. Mallick received his undergraduate degree in Computer Science from Washington University in St. Louis. He then obtained his Ph.D. from UCLA in Chemistry & Biochemistry, where he worked with Dr. David Eisenberg. He completed Post-Doctoral studies at The Institute for Systems Biology, in Seattle, WA with Dr. Ruedi Aebersold. Beyond studying fundamental disease mechanisms, his group has been pioneering novel approaches for enabling personalised and predictive medicine. Most recently, his group has been developing model-based and physics-based approaches to machine learning that enable learning over domains that span a wide range of time and length scales.

Parag Mallik

Alistair is a seasoned pharma executive with more than 25 years of experience in the industry, across manufacturing, consultancy, business and corporate development, data management and clinical operations. Until April 2022 Alistair was CEO of leading, integrated CRO Syneos Health Inc. a role which he held for 6 years. Syneos was the result of a combination of inVentiv Health and INC Research in 2017, of which Alistair was CEO. Alistair led the merger that formed Syneos, which brought together approximately 24,000 employees serving customers in 110 countries with innovative, end-to-end solutions to accelerate their clinical development and commercialisation timelines. Prior to becoming CEO of INC Research, Alistair led multiple functions including Global Business Development and Marketing, Alliances Development and Delivery, Global Oncology, and Clinical Development Services.

Alistair has served as Chair of ACRO, the Association of Clinical Research Organisations, having been on its board for approximately seven years, and is Board Member of the Medicines Discovery Catapult.

Alistair MacDonald

Adam M Hill is the CEO at [Oncimmune](/org/oncimmune).

Adam M Hill

After 20 years in the life sciences industry, Cameron has a unique combination of technical and global commercial experience having served in a range of executive roles for Fortune 500 companies and high growth new ventures across the life sciences research, tools, biomarker development and molecular diagnostics sectors. Cameron started his career in clinical and preclinical imaging R&D, spending 10 years with Agilent Technologies where, as the VP/GM of the laboratory enterprise division, he led the creation of the company’s global strategic account program. More recently, Cameron was the VP/GM of IDEXX Laboratories global bio analytics division (reference laboratories).

Cameron holds degrees in business and engineering technology, information systems and an MBA from the London School of Business. Natively from New Zealand and now based in Boston, USA, Cameron has extensive global experience having lived and worked in Germany, Ireland, Netherlands, Australia, and the UK.

Cameron Barnard

Andrew Unitt

Tim Bunting

Annalisa Jenkins

Matthew Hall is the current Chief Financial Officer at [Oncimmune](/org/oncimmune). Matthew has previously served as the CFO for Tusk Therapeutics, Simbec-Orion Group, and Sphere Medical. Prior to their work in the medical field, Hall served as the Chief Financial Officer for Sinclair IS Pharma plc.

Matthew Hall reports to Adam M Hill, CEO. Matthew Hall works with Cameron Barnard - Chief Business Officer, Ron Kirschner - General Counsel & Company Secretary.

Oncimmune

Org chart

Teams

Board of Directors

Leadership Team

CEO and Executive Team

Discover similar companies